DiscoverPeerPOV: The Pulse on MedicineSERENA-6 at ASCO 2025: ctDNA-Guided Therapy in HR+/HER2- mBC
SERENA-6 at ASCO 2025: ctDNA-Guided Therapy in HR+/HER2- mBC

SERENA-6 at ASCO 2025: ctDNA-Guided Therapy in HR+/HER2- mBC

Update: 2025-08-13
Share

Description

In this episode, Hope Rugo, MD, of City of Hope, shares insights from the SERENA-6 trial, which evaluated ctDNA-guided treatment changes for patients with HR-positive/HER2-negative metastatic breast cancer. 
Let us know what you thought of this week’s episode on Twitter: @physicianswkly
Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com!
Thanks for listening!
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

SERENA-6 at ASCO 2025: ctDNA-Guided Therapy in HR+/HER2- mBC

SERENA-6 at ASCO 2025: ctDNA-Guided Therapy in HR+/HER2- mBC

Physician's Weekly